Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2019
Is Orkambi deal close? Vertex meets again today with NHS England
21 March 2019 - Campaigners hopes rise after three year wait. ...
Posted by Michael Wonder on 20 Mar 2019
Unprecedented drug shortage linked to Brexit, NHS bosses say
20 March 2019 - Hospitals across England are experiencing medicine shortages due to "stockpiling and price pressure as the Brexit ...
Posted by Michael Wonder on 20 Mar 2019
Biosimilar groups offer proposals to help US better mirror EU successes
19 March 2019 - With 18 biosimilars approved in the US and just seven on the market, two biosimilars groups ...
Posted by Michael Wonder on 20 Mar 2019
Biosimilar approval and adoption in the U.S. needs to be expedited
20 March 2019 - Generic versions of brand-name small-molecule drugs saved Americans more than $1 trillion between 1999 and 2010. ...
Posted by Michael Wonder on 20 Mar 2019
Where is the champion for Pharmacare?
20 March 2019 - With the possible exception of a few drug company executives, Canadians overwhelmingly support universal pharmacare — ...
Posted by Michael Wonder on 20 Mar 2019
National drug agency touted as building block of Pharmacare plan
19 March 2019 - The Trudeau Liberals’ new budget promises a new agency to buy drugs in bulk and cut ...
Posted by Michael Wonder on 20 Mar 2019
Senate bill endorses Azar's call to allow drug imports
20 March 2019 - Bipartisan support for a Senate bill that seeks to allow drug importation to boost competition dovetails ...
Posted by Michael Wonder on 20 Mar 2019
Iterum Therapeutics receives QIDP for oral and IV sulopenem in four additional indications as well as fast track designation
19 March 2019 - New designations in community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease demonstrate the ...
Posted by Michael Wonder on 20 Mar 2019
Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic
20 March 2019 - Novo Nordisk today announced the submission of two new drug applications to the US FDA for ...
Posted by Michael Wonder on 20 Mar 2019
FDA reform: it’s time to act, but not as an independent agency
19 March 2019 - In a rare exercise in bipartisan leadership, former FDA commissioners of both political parties called, in ...
Posted by Michael Wonder on 20 Mar 2019
The shadow of Brexit on speed of access
20 March 2019 - No-one can miss the ongoing saga that is the UK’s exit from the European Union. ...
Posted by Michael Wonder on 20 Mar 2019
Partisan squabbles shadow Congress' efforts to lower drug prices
20 March 2019 - It was supposed to be one of the few areas of bipartisanship. ...
Posted by Michael Wonder on 20 Mar 2019
Cancer Society slams PHARMAC's treatment of patients
20 March 2019 - The Cancer Society says New Zealand patients are worse off than those in Australia. ...
Posted by Michael Wonder on 20 Mar 2019
Roche and the pan-Canadian Pharmaceutical Alliance complete negotiations for multiple sclerosis treatment, Ocrevus (ocrelizumab), for both RRMS and PPMS
19 March 2019 - Roche Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a ...
Posted by Michael Wonder on 20 Mar 2019
Canada to create national drug agency to help cut cost of medicines
20 March 2019 - Canada will create a national drug agency to help cut the cost of prescription medications as part ...
Posted by Michael Wonder on 19 Mar 2019
FDA approves first treatment for post-partum depression
19 March 2019 - The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous use for the treatment ...